PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26875919-0	2016	[Inhibition of Sirolimus on the growth of pancreatic carcinoma and its effect on the expression of glucose transporter and hexokinase II].	Sirolimus	15-24	hexokinase 2	Mus musculus	123-136	
26875919-2	2016	METHODS: Sirolimus was applied to treat the pancreatic carcinoma in nude mice orthotopic transplantation model, its difference with the control group was compared; RT-PCR and Western blot were used to measure the mRNA and protein expression of mTOR, HIF-1alpha, Glucose carrier protein 1 (GLUT-1) and Hexokinase II (HK-II), respectively; the changes of activity of HK-II in the tumor was determined.	Sirolimus	9-18	hexokinase 2	Mus musculus	301-314	
26875919-2	2016	METHODS: Sirolimus was applied to treat the pancreatic carcinoma in nude mice orthotopic transplantation model, its difference with the control group was compared; RT-PCR and Western blot were used to measure the mRNA and protein expression of mTOR, HIF-1alpha, Glucose carrier protein 1 (GLUT-1) and Hexokinase II (HK-II), respectively; the changes of activity of HK-II in the tumor was determined.	Sirolimus	9-18	hexokinase 2	Mus musculus	316-321	
26875919-2	2016	METHODS: Sirolimus was applied to treat the pancreatic carcinoma in nude mice orthotopic transplantation model, its difference with the control group was compared; RT-PCR and Western blot were used to measure the mRNA and protein expression of mTOR, HIF-1alpha, Glucose carrier protein 1 (GLUT-1) and Hexokinase II (HK-II), respectively; the changes of activity of HK-II in the tumor was determined.	Sirolimus	9-18	hexokinase 2	Mus musculus	365-370	
26875919-5	2016	The activity of HK-II in the control group was higher than that of the Sirolimus group (P<0.05).	Sirolimus	71-80	hexokinase 2	Mus musculus	16-21	
26875919-6	2016	CONCLUSION: Sirolimus could affect the expression of GLUT-1 and HK-II in pancreatic carcinoma through the effects of HIF-1alpha to inhibit tumor growth, indicating that blocking the mTOR pathway could control the glycolytic metabolism pathways of pancreatic carcinoma, which may become the new strategy for the treatment of pancreatic carcinoma.	Sirolimus	12-21	hexokinase 2	Mus musculus	64-69	
31399190-7	2019	We found that Rapa blocked glycolysis in induced Th17 cells, evidenced by reduced glucose uptake, and inhibited expression of glucose transporter 1 and the rate-limiting enzyme HK2.	Sirolimus	14-18	hexokinase 2	Mus musculus	177-180